Management of antithrombotic therapy in patients with multiple cardiovascular risk factors and enhancers and no history of symptomatic ASCVD
| . | Severe infections where only preventive antithrombotic treatment is indicated . | Severe infections and platelet count ≥20 × 109/L . | Severe infections and platelet count <20 × 109/L . | Severe infections and platelet count <20 × 109/L in the presence of multiorgan failure . |
|---|---|---|---|---|
| During | No routine antiplatelet therapy, SAPT as pre-existing indication | No routine antiplatelet therapy, SAPT as pre-existing indication | No antiplatelet therapy | No antithrombotic treatment |
| Prophylactic anticoagulationa | Prophylactic anticoagulation | Prophylactic anticoagulation in patients at high thromboembolic risk | ||
| After | SAPT as pre-existing indication | SAPT as pre-existing indication | SAPT as pre-existing indication | SAPT as pre-existing indication |
| No routine prophylactic anticoagulationb | No routine prophylactic anticoagulationb | No routine prophylactic anticoagulationb | No routine prophylactic anticoagulationb |
| . | Severe infections where only preventive antithrombotic treatment is indicated . | Severe infections and platelet count ≥20 × 109/L . | Severe infections and platelet count <20 × 109/L . | Severe infections and platelet count <20 × 109/L in the presence of multiorgan failure . |
|---|---|---|---|---|
| During | No routine antiplatelet therapy, SAPT as pre-existing indication | No routine antiplatelet therapy, SAPT as pre-existing indication | No antiplatelet therapy | No antithrombotic treatment |
| Prophylactic anticoagulationa | Prophylactic anticoagulation | Prophylactic anticoagulation in patients at high thromboembolic risk | ||
| After | SAPT as pre-existing indication | SAPT as pre-existing indication | SAPT as pre-existing indication | SAPT as pre-existing indication |
| No routine prophylactic anticoagulationb | No routine prophylactic anticoagulationb | No routine prophylactic anticoagulationb | No routine prophylactic anticoagulationb |
ASCVD, atherosclerotic cardiovascular disease; SAPT, single antiplatelet therapy, usually low-dose aspirin.
Therapeutic dose anticoagulation may be considered in patients without high risk of bleeding.
Thromboprophylaxis may be considered in high-risk patients (persistent immobility, history of venous thromboembolism, advanced age, obesity, cancer, thrombophilia, increased D-dimer concentrations, and high inflammatory activity) and low risk of bleeding.
Management of antithrombotic therapy in patients with multiple cardiovascular risk factors and enhancers and no history of symptomatic ASCVD
| . | Severe infections where only preventive antithrombotic treatment is indicated . | Severe infections and platelet count ≥20 × 109/L . | Severe infections and platelet count <20 × 109/L . | Severe infections and platelet count <20 × 109/L in the presence of multiorgan failure . |
|---|---|---|---|---|
| During | No routine antiplatelet therapy, SAPT as pre-existing indication | No routine antiplatelet therapy, SAPT as pre-existing indication | No antiplatelet therapy | No antithrombotic treatment |
| Prophylactic anticoagulationa | Prophylactic anticoagulation | Prophylactic anticoagulation in patients at high thromboembolic risk | ||
| After | SAPT as pre-existing indication | SAPT as pre-existing indication | SAPT as pre-existing indication | SAPT as pre-existing indication |
| No routine prophylactic anticoagulationb | No routine prophylactic anticoagulationb | No routine prophylactic anticoagulationb | No routine prophylactic anticoagulationb |
| . | Severe infections where only preventive antithrombotic treatment is indicated . | Severe infections and platelet count ≥20 × 109/L . | Severe infections and platelet count <20 × 109/L . | Severe infections and platelet count <20 × 109/L in the presence of multiorgan failure . |
|---|---|---|---|---|
| During | No routine antiplatelet therapy, SAPT as pre-existing indication | No routine antiplatelet therapy, SAPT as pre-existing indication | No antiplatelet therapy | No antithrombotic treatment |
| Prophylactic anticoagulationa | Prophylactic anticoagulation | Prophylactic anticoagulation in patients at high thromboembolic risk | ||
| After | SAPT as pre-existing indication | SAPT as pre-existing indication | SAPT as pre-existing indication | SAPT as pre-existing indication |
| No routine prophylactic anticoagulationb | No routine prophylactic anticoagulationb | No routine prophylactic anticoagulationb | No routine prophylactic anticoagulationb |
ASCVD, atherosclerotic cardiovascular disease; SAPT, single antiplatelet therapy, usually low-dose aspirin.
Therapeutic dose anticoagulation may be considered in patients without high risk of bleeding.
Thromboprophylaxis may be considered in high-risk patients (persistent immobility, history of venous thromboembolism, advanced age, obesity, cancer, thrombophilia, increased D-dimer concentrations, and high inflammatory activity) and low risk of bleeding.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
